Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102

• Status: Completed
• Trial end date: 2021-04-30
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2101 and AD-2102 in healthy male subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Addpharma Inc.

Criteria

Inclusion Criteria:

• Healthy male between 19 and 50 years of age at the time of screening

• Weight above 50 kg and body mass index (BMI) between 17.5 kg/m2 and 30.5 kg/m2

Exclusion Criteria:

• Clinically significant disease or history of clinically significant disease such as cardiovascular, respiratory, liver, kidney, digestive, hematologic/oncologic, endocrine, immunologic, urinary, psychiatric

• Gastrointestinal problem or history of gastrointestinal problem and history of gastrointestinal surgery

• A person who has a history of drug abuse

• AST, ALT, Total bilirubin values over than 2 times of UNL at screening

• Creatinine clearance under 80mL/min